|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003440,
umls-concept:C0026336,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0040053,
umls-concept:C0042444,
umls-concept:C0042460,
umls-concept:C0220825,
umls-concept:C0348005,
umls-concept:C0524527,
umls-concept:C0668961
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-9-15
|
|
pubmed:abstractText |
The objective of this study was to investigate whether the use of a depot formulation would enhance the antithrombotic effect of the direct thrombin inhibitor melagatran.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0142-2782
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 John Wiley & Sons, Ltd.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
251-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12973822-Animals,
pubmed-meshheading:12973822-Antithrombins,
pubmed-meshheading:12973822-Azetidines,
pubmed-meshheading:12973822-Benzylamines,
pubmed-meshheading:12973822-Chemistry, Pharmaceutical,
pubmed-meshheading:12973822-Constriction, Pathologic,
pubmed-meshheading:12973822-Cyclodextrins,
pubmed-meshheading:12973822-Delayed-Action Preparations,
pubmed-meshheading:12973822-Disease Models, Animal,
pubmed-meshheading:12973822-Drug Evaluation, Preclinical,
pubmed-meshheading:12973822-Endothelium, Vascular,
pubmed-meshheading:12973822-Glycine,
pubmed-meshheading:12973822-Injections, Subcutaneous,
pubmed-meshheading:12973822-Male,
pubmed-meshheading:12973822-Partial Thromboplastin Time,
pubmed-meshheading:12973822-Pharmaceutical Vehicles,
pubmed-meshheading:12973822-Poloxamer,
pubmed-meshheading:12973822-Rats,
pubmed-meshheading:12973822-Rats, Sprague-Dawley,
pubmed-meshheading:12973822-Solutions,
pubmed-meshheading:12973822-Sweden,
pubmed-meshheading:12973822-Thrombin Time,
pubmed-meshheading:12973822-Vena Cava, Inferior,
pubmed-meshheading:12973822-Venous Thrombosis
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
|
|
pubmed:affiliation |
Department of Integrative Pharmacology, AstraZeneca R and D, Mölndal, Sweden. Margareta.Elg@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
